☰

Darryl L. Kato, Ph.D. - Publications

Affiliations: 
2007 Harvard University, Cambridge, MA, United States 
Area:
Organic synthesis
Tree Info Similar researchers PubMed Report error

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Link JO, Taylor JG, Trejo-Martin A, Kato D, Katana AA, Krygowski ES, Yang ZY, Zipfel S, Cottell JJ, Bacon EM, Tran CV, Yang CY, Wang Y, Wang KW, Zhao G, et al. Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi and Epclusa. Bioorganic & Medicinal Chemistry Letters. PMID 31230974 DOI: 10.1016/J.Bmcl.2019.04.027  0.372
2019 Taylor JG, Zipfel S, Ramey K, Vivian R, Schrier A, Karki KK, Katana A, Kato D, Kobayashi T, Martinez R, Sangi M, Siegel D, Tran CV, Yang ZY, Zablocki J, et al. Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi. Bioorganic & Medicinal Chemistry Letters. PMID 31133531 DOI: 10.1016/J.Bmcl.2019.03.037  0.439
2016 Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, Kato D, Kirschberg T, Sun J, Squires N, Parrish J, Kellar T, Yang ZY, Yang C, Matles M, et al. Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry. PMID 27529494 DOI: 10.1021/acs.jmedchem.6b01043  0.345
2015 Kwon HJ, Xing W, Chan K, Niedziela-Majka A, Brendza KM, Kirschberg T, Kato D, Link JO, Cheng G, Liu X, Sakowicz R. Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. Plos One. 10: e0122844. PMID 25856426 DOI: 10.1371/journal.pone.0122844  0.329
2014 Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, Kato D, Kirschberg T, Sun J, Squires N, Parrish J, Keller T, Yang ZY, Yang C, Matles M, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. Journal of Medicinal Chemistry. 57: 2033-46. PMID 24320933 DOI: 10.1021/jm401499g  0.411
2010 Fortner KC, Kato D, Tanaka Y, Shair MD. Enantioselective synthesis of (+)-cephalostatin 1. Journal of the American Chemical Society. 132: 275-80. PMID 19968285 DOI: 10.1021/Ja906996C  0.393
Show low-probability matches.